From: Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
Characteristic, n (%) | N = 57 |
---|---|
Age, years, median (range) | 32.0 (19.0–77.0) |
Sex, n (%) | |
Male | 24 (42.1) |
Female | 33 (57.9) |
Race, n (%) | |
White | 44 (77.2) |
Black or African American | 8 (14.0) |
Asian | 1 (1.8) |
Pacific Islander | 3 (5.3) |
Other | 1 (1.8) |
ECOG performance status, n (%) | |
0 | 32 (56.1) |
1 | 23 (40.4) |
2 | 2 (3.5) |
Hodgkin lymphoma classification, n (%) | |
Classical nodular sclerosis | 52 (91.2) |
Classical mixed cellularity | 3 (5.3) |
Other | 2 (3.5) |
Stage at diagnosis, n (%) | |
I | 2 (3.5) |
II | 20 (35.1) |
III | 18 (31.6) |
IV | 17 (29.8) |
Number of previous regimens, median (range) | 4 (1–17) |
Previous treatment, n (%) | |
AHSCT | 38 (66.7) |
Gemcitabine-containing regimen | 32 (56.1) |
Vinorelbine-containing regimen | 23 (40.4) |
Vinblastine-containing regimen | 55 (96.5) |
Disease progression during previous therapy, n (%) | 38 (66.7) |
Time from diagnosis to first recurrence/relapse, months, median (range) | 11.1 (0.6–80.0) |
Time from diagnosis to most recent recurrence/relapse, months, median (range) | 38.9 (7.0–221.4) |